ArticleNucleic acids research2025
A versatile plug and play bacterial chassis based on a fast-growing Mycoplasma species.
Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
An easy engineerable bacterial chassis opens a spectrum of biomedical applications such as antigen or drug delivery. However, most cell-walled bacteria are readily recognized and cleared by the immune system and encode various effector proteins potentially interacting with the target species. Mycoplasma feriruminatoris, a cell-wall-less minimal organism with excellent growth attributes, was genetically engineered to stably and almost seamlessly incorporate foreign DNA fragments into the chromosome in a single step using an orthogonal recombinase system. Using this mechanism, we characterized and developed promoters and proved their functionality, including a kill-switch based on a temperature-sensitive promoter that drives expression of a toxin from a toxin-antitoxin system. Additionally, we designed a streptavidin-based functional dynamic display system at the surface of the bacterium. The engineered strains have great potential such as to deliver vaccine antigens to different livestock species among other biomedical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.